Orexigen Therapeutics is a biopharmaceutical company which focuses on the development of pharmaceutical product candidates for the treatment of obesity. The Company's product, Contrave, is approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. Its solution is a prescription medicine that contains 2 medicines (naltrexone HCl and bupropion HCl) that may help some obese adults, or overweight adults who also have weight-related medical problems, lose weight and keep the weight off.
State | Closed | |
Type | Private | |
Founded | 2002 | |
HQ | San Diego, CA, US | Map |
Website | orexigen.com | |
Employee Ratings | More |
Founding Date | 2002 |
Orexigen Therapeutics total Funding | $76 m |
Orexigen Therapeutics latest funding size | $30 m |
Time since last funding | 14 years ago |
Orexigen Therapeutics investors | Kleiner Perkins, Scale Venture Partners, Montreux Equity Partners, MPM Capital, Duke University, Domain Associates, Wasatch Advisors |
USD | |
---|---|
Revenue (Q3, 2017) | 18.9m |
Gross profit (Q3, 2017) | 14.9m |
Gross profit margin (Q3, 2017), % | 78.6% |
Net income (Q3, 2017) | (20.8m) |
EBIT (Q3, 2017) | (22.8m) |
Cash (30-Sept-2017) | 45.6m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 857.0k | 857.0k | 857.0k | 857.0k | 857.0k | 857.0k | 857.0k | 857.0k | 857.0k | 857.0k | 30.9m | 4.4m | 5.2m | 10.0m | 5.0m | 7.8m | 7.0m | 19.1m | 23.4m | 18.9m |
Cost of goods sold | 1.8m | 1.9m | 6.2m | 6.8m | 4.0m | |||||||||||||||
Gross profit | 6.0m | 5.1m | 13.0m | 16.5m | 14.9m | |||||||||||||||
Gross profit Margin, % | 77% | 72% | 68% | 71% | 79% |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 36.4m | 33.9m | 73.4m | 67.4m | 56.1m | 67.1m | 55.8m | 48.7m | 37.6m | 31.1m | 68.4m | 75.1m | 71.6m | 154.3m | 68.0m | 78.2m | 74.4m | 76.7m | 36.7m | 45.6m |
Accounts Receivable | 32.0m | 4.5m | 6.8m | 4.6m | 2.8m | 2.9m | 2.1m | 6.3m | 7.6m | 19.1m | ||||||||||
Prepaid Expenses | 1.3m | 897.0k | 1.3m | 2.3m | 1.5m | 2.0m | 3.0m | 1.8m | 1.3m | 5.8m | 1.8m | 1.3m | 2.0m | 2.2m | 2.6m | 4.0m | 6.1m | 4.9m | 4.3m | 6.5m |
Inventories | 754.0k | 1.4m | 4.9m | 11.1m | 15.0m | 11.5m | 24.0m | 20.7m | 15.8m | 16.1m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (19.2m) | (23.8m) | (10.4m) | (27.1m) | (57.6m) | (19.4m) | (37.6m) | (56.2m) | (24.9m) | (49.4m) | (38.1m) | (17.2m) | (39.7m) | (50.9m) | (22.3m) | (47.6m) | 85.0k | (69.1m) | (99.6m) | (120.4m) |
Depreciation and Amortization | 240.0k | 348.0k | 83.0k | 160.0k | 236.0k | 76.0k | 79.0k | 84.0k | 8.0k | 46.0k | 87.0k | 51.0k | 103.0k | 157.0k | 78.0k | 194.0k | 1.7m | 2.1m | 4.2m | 6.3m |
Inventories | (754.0k) | (158.0k) | (3.7m) | (9.8m) | (4.1m) | (596.0k) | 618.0k | 2.4m | 7.6m | 7.6m | ||||||||||
Accounts Payable | (4.8m) | (6.8m) | 725.0k | 4.1m | 13.5m | (4.7m) | (6.4m) | (4.2m) | (1.2m) | 1.7m | (1.1m) | (3.8m) | 6.9m | 4.0m | (1.9m) | 2.5m | 13.1m | 3.5m | (5.5m) | 10.5m |
USD | Q2, 2011 |
---|---|
Financial Leverage | 3.8 x |
When was Orexigen Therapeutics founded?
Orexigen Therapeutics was founded in 2002.
How many employees does Orexigen Therapeutics have?
Orexigen Therapeutics has 132 employees.
What is Orexigen Therapeutics revenue?
Latest Orexigen Therapeutics annual revenue is $33.7 m.
What is Orexigen Therapeutics revenue per employee?
Latest Orexigen Therapeutics revenue per employee is $255.4 k.
Who are Orexigen Therapeutics competitors?
Competitors of Orexigen Therapeutics include Otonomy, Ironwood Pharmaceuticals and Biogen.
Where is Orexigen Therapeutics headquarters?
Orexigen Therapeutics headquarters is located at 200 3344 N Torrey Pines Ct, San Diego.
Where are Orexigen Therapeutics offices?
Orexigen Therapeutics has an office in San Diego.
How many offices does Orexigen Therapeutics have?
Orexigen Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies